PACB Key Statistics, Chart & Performance
The current stock price of PACB is 1.74 USD. In the past month the price decreased by -26.29%. In the past year, price decreased by -14.07%.
PACB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 25.94 | 218.29B | ||
| DHR | DANAHER CORP | 29.83 | 162.45B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 187.31 | 56.92B | ||
| A | AGILENT TECHNOLOGIES INC | 24.58 | 38.88B | ||
| IQV | IQVIA HOLDINGS INC | 19.54 | 38.70B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 33.68 | 28.79B | ||
| WAT | WATERS CORP | 30.07 | 22.74B | ||
| ILMN | ILLUMINA INC | 30.5 | 20.32B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 38.83 | 19.75B | ||
| MEDP | MEDPACE HOLDINGS INC | 39.69 | 15.99B | ||
| RVTY | REVVITY INC | 20.34 | 11.04B | ||
| TEM | TEMPUS AI INC | N/A | 10.86B |
Related stock screener links
About PACB
Company Profile
Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. The company is headquartered in Menlo Park, California and currently employs 575 full-time employees. The company went IPO on 2010-10-27. The company is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. The company has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which detects the nucleotide sequence and epigenetic status of individual deoxyribonucleic acid molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.
Company Info
PACIFIC BIOSCIENCES OF CALIF
1305 O'brien Drive
Menlo Park CALIFORNIA 94025 US
CEO: Christian O. Henry
Employees: 575
Phone: 16505218000
PACIFIC BIOSCIENCES OF CALIF / PACB FAQ
What does PACIFIC BIOSCIENCES OF CALIF do?
Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. The company is headquartered in Menlo Park, California and currently employs 575 full-time employees. The company went IPO on 2010-10-27. The company is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. The company has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which detects the nucleotide sequence and epigenetic status of individual deoxyribonucleic acid molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.
What is the current price of PACB stock?
The current stock price of PACB is 1.74 USD. The price increased by 1.75% in the last trading session.
What is the dividend status of PACIFIC BIOSCIENCES OF CALIF?
PACB does not pay a dividend.
How is the ChartMill rating for PACIFIC BIOSCIENCES OF CALIF?
PACB has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting PACB stock to perform?
17 analysts have analysed PACB and the average price target is 2.36 USD. This implies a price increase of 35.56% is expected in the next year compared to the current price of 1.74.
Is PACIFIC BIOSCIENCES OF CALIF (PACB) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PACB.
What is the market capitalization of PACB stock?
PACIFIC BIOSCIENCES OF CALIF (PACB) has a market capitalization of 525.32M USD. This makes PACB a Small Cap stock.
PACB Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to PACB. When comparing the yearly performance of all stocks, PACB turns out to be only a medium performer in the overall market: it outperformed 43.03% of all stocks.
PACB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PACB. PACB has a bad profitability rating. Also its financial health evaluation is rather negative.
PACB Financial Highlights
Over the last trailing twelve months PACB reported a non-GAAP Earnings per Share(EPS) of -2.2. The EPS decreased by -50.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -62.71% | ||
| ROE | -1395.49% | ||
| Debt/Equity | 17.88 |
PACB Forecast & Estimates
17 analysts have analysed PACB and the average price target is 2.36 USD. This implies a price increase of 35.56% is expected in the next year compared to the current price of 1.74.
For the next year, analysts expect an EPS growth of 1.11% and a revenue growth 1.86% for PACB